Targeted $50M. Raised $55M. Thirty Days. No Pitch Deck. No Placement Agent. Every Dollar Inbound.

DALLAS, May 13, 2026 — Champion Leadership Group today announced the final close of SaaS Fuel™ Fund I at $55 million, oversubscribed from its original $50 million target and completed in under 30 days without a road show, a placement agent, a pitch deck, or a single cold outreach. Every dollar came inbound — from exited SaaS founders and senior technology executives who had worked directly with the firm.

Fund I targets approximately 30 B2B SaaS and AI companies in the $1M–$5M ARR range — the most structurally neglected stage in SaaS investment, too large for friends-and-family capital and too small for institutional funds whose check sizes require dilutive ownership at this valuation. Each portfolio company receives capital plus the full SaaS Fuel™ operational infrastructure: the SaaS Fuel Operating System™, the firm’s proprietary infrastructure trained on 81,000 closed private-market transactions; a monthly podcast reaching 12,000 founders; an email community of 17,000 operators; and the Founder Flywheel™ network connecting portfolio founders with exited operators who serve as advisors, early customers, and follow-on investors. Initial checks range from $500k – $3M, with reserved capital for future rounds.

The fund’s economic structure is built on the same alignment philosophy. The fund charges no management fee — a deliberate departure from the industry-standard 2% that would otherwise draw $1.1 million annually from investor capital regardless of performance. Carry is 20%, but only after a 9% preferred return hurdle: every LP receives their capital back plus a 9% annual return before any carry is distributed. Managing Partner Jeff Mains committed $5 million of personal capital — nearly 10% of the fund — at identical terms to every LP. Same entry. Same hurdle. Same lock-up. No exceptions.

When inbound commitments exceeded the $50M target, Mains chose to expand modestly rather than turn away the founders and operators who had been closest to the work over the longest period of time.

“Every person who invested had watched us work,” said Mains. “The oversubscription was not a marketing outcome — it was a trust outcome. That distinction matters more than most people in venture are willing to admit.”

The firm currently serves 240 active founder clients through its accelerator program. A Fund II has not been announced; the firm is focused on full deployment of Fund I. Fund I is actively investing.

About Champion Leadership Group
Champion Leadership Group is a Dallas, Texas-based B2B SaaS and AI scale-up accelerator and investment firm. SaaS Fuel™ Fund I — $55 million, no management fee, 20% carry after a 9% preferred return hurdle, $5M GP commitment at identical LP terms — closed oversubscribed in under 30 days. The SaaS Fuel Operating System™ is trained on 81,000 closed private-market transactions. Jeff Mains: five companies built, four exits. 240 active founder clients. Fund I is actively investing.

Media Contact:
Alex Carter, Media Relations
Champion Leadership Group
469-640-8545
[email protected]

SOURCE Champion Leadership Group

Partnering with leading pharmaceutical companies, BranchLab replaces fragmented, offline workflows with a unified, privacy-first AI platform—driving a nearly 70% increase in commercialization efficacy.

BOULDER, Colo., May 13, 2026 — BranchLab, an AI platform transforming how pharmaceutical companies commercialize therapies, today announced a $26 million Series A financing led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. The round brings total funding to $35 million.

Pharma commercialization—spanning patient identification, audience segmentation, activation, and real-world measurement—has historically relied on fragmented vendors, delayed analytics, and manual workflows. The result is a system that is data-rich but operationally offline, limiting how quickly teams can learn, adapt, and drive impact.

BranchLab is changing that.

The company has built a unified AI platform that puts audience identification, activation, and optimization directly in the hands of pharma teams and their agencies—enabling them to act on high-intent patient and healthcare professional (HCP) audiences in near real time. Today, BranchLab is used by leading pharmaceutical companies and has delivered an average increase of nearly 70% in marketing efficacy across a diverse set of therapeutic areas.

“Pharma has long had access to rich data, but using it quickly—and responsibly—has been the challenge,” said Josh Walsh, CEO of BranchLab. “BranchLab solves this by turning privacy-safe, aggregated data into real-time insights that connect directly to activation. Teams can move faster, reach the right audiences more effectively, and drive better outcomes without relying on sensitive or individual-level information.”

At the core of the platform is a novel transformer-based architecture that enables models to train on health data within customer-controlled environments, while deploying only non-sensitive demographic and media-side signals. The new approach transforms commercialization workflows that used to take months and collapses them to minutes.

“The more we learned about BranchLab, the more we saw the possibility to transform the way patients learn about and get started on the right therapies,” said Carrie Williams, partner at McKesson Ventures. “Combining a deep understanding of the patient journey with a future-proofed approach to patient activation could enable an evolved patient therapy experience, one that seamlessly bridges privacy-first audience targeting with patient access, affordability and preference.”

FCA emphasized the underlying system shift: “Pharma has spent years investing in data and analytics, but much of it still lives outside of production systems,” said Andrew Bouldin, Managing Partner at FCA Venture Partners. “BranchLab’s approach to running models within regulated environments and connecting them directly to execution is a fundamental shift in how commercialization can work. We see this as a meaningful step toward making pharma’s data, and activation systems work together in real time.”

Sanofi Ventures highlighted the broader industry shift toward embedded, privacy-aware AI systems.

“Healthcare is entering a new era of responsible AI within regulated environments,” said Cris De Luca, Sanofi Ventures. “BranchLab has the potential to become a core commercial intelligence layer, putting this capability directly in the hands of pharma teams to connect therapies with patients across next‑generation digital environments.”

As the industry moves toward faster, more accountable, and privacy-first systems, BranchLab is positioning itself as the infrastructure layer for how therapies are brought to market in the AI era.

With the new funding, BranchLab will expand enterprise deployments, deepen integrations across the healthcare and media ecosystem, and continue building the unified AI platform for pharma commercialization.

About BranchLab
BranchLab is transforming healthcare commercialization with AI-native technology that helps leading healthcare organizations and their agencies connect patients, providers, and caregivers to life-improving therapies and resources. Built for the evolving privacy landscape, BranchLab improves commercialization performance without relying on individual-level health information. By modernizing the industry’s technical infrastructure, BranchLab helps organizations operate more efficiently and responsibly, while enabling a healthier system for everyone.

To learn more, visit www.branchlab.com.

CONTACT:
BranchLab Media Team
[email protected]

SOURCE BranchLab Inc

New capital fuels product enhancements as leading biopharma adopt QuartzBio to eliminate operational inefficiencies and protect trial outcomes

BALTIMORE, May 13, 2026 — QuartzBio, a life science technology company delivering portfolio‑scale sample and biomarker intelligence for clinical‑stage biopharma, today announced a strategic growth investment and controlling interest from Eir Partners, a private equity firm focused on health tech and tech-enabled services. The move marks a significant milestone as QuartzBio expands its role as trusted infrastructure for biopharma organizations seeking greater operational control, data integrity, and efficiency across complex clinical trial portfolios.

Addressing a Growing Operational Bottleneck in Clinical Development
As clinical trial portfolios scale, sponsors are forced to manage biospecimens and biomarker data across disconnected vendors, systems, and spreadsheets. This fragmentation introduces operational blind spots—driving missing or unusable samples, manual consent and collection tracking, late discovery of data gaps, costly downstream rework, and trial delays.

QuartzBio was built to eliminate this friction. Its vendor‑agnostic, AI‑enabled platform unifies sample collection, chain of custody, consent status, metadata integrity, and biomarker results into a single ecosystem—delivering real‑time visibility and control across entire clinical portfolios.

Proven Impact Across Clinical Operations
QuartzBio is trusted by a growing customer base that includes multiple Top 10 pharmaceutical companies, delivering operational clarity across complex clinical programs. The platform helps teams identify and resolve issues early—before they become protocol deviations, data loss, or trial delays—while integrating seamlessly into existing workflows.

Customers report near‑complete visibility into sample collection, reducing monitoring effort by up to 98% and significantly cutting manual work through automated oversight and exception management—allowing teams to support significantly more studies without adding headcount. These efficiencies drive $250K–$350K in average savings per Phase II/III study, while protecting timelines and ensuring biomarker‑ready data at readout.

By embedding domain‑specific AI directly into clinical and translational workflows, QuartzBio enables R&D teams to move faster and with greater confidence—without increasing operational risk or administrative burden.

Focused Investment in Product and Scale
The investment from Eir Partners enables QuartzBio to accelerate enhancements across its platform and operating model, including:

• Expanded portfolio‑scale interoperability across CROs, labs, and clinical systems
   
• Deeper AI‑driven automation for workflow management, risk detection, and data completeness
   
• Enhanced analytics and benchmarking for multi-trial decision‑making
   
• Increased enterprise scalability, security, and global compliance
   
• Expanded customer support and implementation capacity to match growing adoption

“Modern clinical development generates unprecedented volumes of data, yet trial risk persists because that data is fragmented, delayed, or unreliable,” said Scott Marshall, Ph.D., CEO of QuartzBio. “This investment allows us to double down on delivering a scalable software platform that removes manual oversight, protects scientific integrity, and materially reduces trial cost and duration.”

Investor Perspective
“AI is fundamentally transforming clinical development, and sample and biomarker intelligence represents one of its highest-impact applications,” said Brett Carlson, Founder and Chief Executive Officer of Eir Partners. “QuartzBio has demonstrated both strong product‑market fit and tangible economic impact for sponsors managing complex portfolios. By embedding domain-specific AI directly into clinical and translational workflows, the company is well positioned to shape how next-generation trials are conducted.”

Terms of the transaction with Eir Partners were not disclosed. Bourne Partners served as an exclusive financial advisor to QuartzBio.

About QuartzBio
QuartzBio is a life science technology company delivering connected sample and biomarker intelligence for clinical-stage biopharma. Designed for modern, multi-trial portfolios, its vendor‑agnostic platform unifies sample operations and biomarker data into a single platform—powered by domain‑specific AI agents—to reduce operational risk, accelerate timelines, and enable scientifically defensible outcomes. For more information, please visit their website at www.quartzbio.com or LinkedIn page.

About Eir Partners
Eir Partners Capital is a Miami-based private equity company focused on healthcare technology and tech-enabled services. Founded in 2015, Eir has partnered with entrepreneurs and management teams to create scaled, strategically differentiated platforms across payer, provider, employer, and pharma technology sectors. The Firm’s hands-on approach combines operational insight with deep industry relationships to drive long-term value. Targeted stages of investment include growth equity through control buyouts and equity check sizes range from $40 – $150 million or larger with co-investments. For more information, please visit their website at www.eirpartners.com or LinkedIn page.

SOURCE QuartzBio

Led by SignalFire and HubSpot Ventures, the round backs Vector’s vision for contact-level advertising and a new interface that lets marketers talk to their data

BOSTON, May 13, 2026 — Vector, the contact-level advertising platform for B2B marketers, today announced a $10M Series A, led by SignalFire and HubSpot Ventures.

The funding will accelerate Vector’s development of an AI ad automation platform built to multiply the impact of B2B marketers, not replace them. Alongside the raise, Vector is launching Vector MCP, the only interface that brings Vector’s unique ability to associate de-anonymized ad clickers with ad performance data into LLMs like Claude and ChatGPT. This allows marketers to query campaign performance and buyer activity in natural language instead of digging through dashboards.

“Every marketer we talk to is trying to do more with the same budget and prove it’s working. Vector gives them something that hasn’t existed before, the ability to target specific buyers based on real intent signals in real time. We see the opportunity to connect all the dots in a buyer’s journey and optimize marketing touch-points based on what is working,” said Adam Coccari, Managing Director at HubSpot Ventures. “We’re excited to partner with the team as they build essential infrastructure for our shared customers and beyond.”

Vector pioneered contact-level advertising, helping marketers target named buyers based on intent signals like website visits, ad clicks, and competitor research.

“The teams that win in B2B GTM will be the ones who capture the right signals early, before intent is obvious and before a competitor gets there first. Vector has built something new: contact-level advertising that transforms anonymous interest into actionable signals and named audiences,” said Varun Ramakrishnan, Principal at SignalFire. “SignalFire invested because we believe that’s foundational to how modern marketers will build pipeline.”

With this investment, the company is building toward a future where AI handles the repetitive work so marketers can focus on strategy and creative, the parts requiring human taste and judgment. Vector MCP is the first step, letting marketers ask plain-language questions about their campaigns and buyer activity, and get answers without switching between platforms or waiting on reports.

“The prevailing narrative right now is that AI will replace your marketing team. We think that’s wrong,” said Joshua Perk, co-founder and CEO of Vector. “The real opportunity is using AI to compound what good marketers already do. We’re not building a product that takes the marketer out of the loop. We’re building one that gives them better data, faster answers, and the ability to operate at a scale that wasn’t possible before.”

About Vector

Vector is the contact-level advertising platform built for B2B marketers. Vector enables demand gen and ABM teams to build ad audiences by name—targeting the exact buyers they care about, not just companies or vague firmographic filters. Leading B2B marketers use Vector to run more precise campaigns, reduce wasted ad spend, and prove the impact of their programs. Backed by SignalFire and HubSpot Ventures.

SOURCE Vector

The latest financing marks a new phase of scale as Oishii grows production, expands retail access, and advances its operations across the United States and Japan

JERSEY CITY, N.J., May 13, 2026 — Oishii, the company behind the world’s largest indoor vertical strawberry farm, today announced the first closing of $150 million in Series C financing led by SPARX Asset Management Co., Ltd., with participation from Nomura Real Estate Development Co., Ltd., MISUMI Group Inc., Mizuho Bank Ltd., and others. The financing reflects confidence in Oishii’s indoor Smart Farm™ model—which integrates robotics, automation, and advanced technology with centuries-old Japanese farming techniques—as the company increases production, advances farm operations, and broadens retail access to its pesticide-free, Non-GMO strawberries, which are grown year-round and harvested at peak ripeness.

While the vertical farming sector has cooled in recent years, Oishii has continued to gain momentum through a more focused approach to scale, using robotics and automation, broader consumer access, and continued technology innovation to differentiate itself within the category. Oishii has expanded its distribution across 18 states, launched in Toronto as its first international retail market, introduced new retail formats and product offerings, and is now advancing its R&D capabilities in Japan through the development of its first-of-its-kind Open Innovation Center in Tokyo.

Robotics and automation have become central to Oishii’s approach to scaling strawberry production with greater consistency, precision, and quality control. Following the acquisition of Tortuga AgTech in 2025, the company expanded those capabilities with additional harvesting robotics and engineering expertise. Earlier this year, Oishii also announced a strategic partnership with MISUMI Group Inc., a global supplier of manufacturing and automation components, to support its growing automation and manufacturing needs across the U.S. and Japan.

“Since our Series A investment in 2019, we have continuously supported Oishii Farm’s growth. It is truly inspiring to see the vision we shared at that time steadily becoming a reality, as the company advances seamlessly from research and development to proof of concept and commercialization,” said Shuhei Abe, President & CEO of SPARX Asset Management Co., Ltd. “One of the company’s key strengths lies in its exceptional execution capability, which has enabled rapid technological advancement. As Oishii Farm enters a new phase with the establishment of its Open Innovation Center in Japan, we look forward to continuing to support its growth.”

Oishii has also expanded beyond its original ultra-premium positioning into a more flexible retail business with broader consumer reach. Since launching the Omakase Berry at nearly $50 per tray in 2018, the company has added the Koyo Berry and Nikko Berry and introduced new pack sizes and retail formats designed for more everyday purchasing, with offerings today spanning $4.99 to $15. Its new Premium Preserves line also extends the brand beyond fresh berries into an elevated range of pantry staples.

The Nikko Berry, introduced in 2025, has also become a strong proof point for how Oishii applies demand, retail, and production insight to product innovation. Earlier this year, the company introduced its innovative stay-fresh top-seal packaging for the Nikko Berry, advancing a new approach to strawberry packaging focused on freshness, shelf life, and retail scalability while reducing plastic usage by 80% compared to traditional clamshell packaging.

Together, these milestones show Oishii entering a new phase of maturity and growth, scaling its differentiated model to expand production, reach more consumers, and help define the next phase of indoor vertical farming.

“When we chose strawberries, we knew we were selecting one of the hardest paths in indoor farming,” said Hiroki Koga, Co-Founder and CEO of Oishii. “They require precision at every stage, from pollination and harvesting to freshness and shelf life, and there were moments along the way where solving one challenge revealed the next one underneath it. This funding marks a new phase for Oishii as we scale what we’ve built, with deeper confidence in the decisions we’ve made and the role we can play in bringing high-quality produce to more people.”

With the first closing of Series C financing, Oishii plans to increase production capacity, advance robotics integration, expand farm infrastructure, and develop new product formats within its Smart Farm model, while continuing to invest in R&D and innovation capabilities across the United States and Japan.

Oishii has raised a total of $370M since its founding in 2016.

About Oishii
Oishii (which means “delicious” in Japanese) is the innovative company behind the world’s largest indoor vertical Smart Farm™. On a mission to transform the agriculture industry through the power of smart farming, Oishii harmoniously marries nature with state-of-the-art technology to create the ideal elements—rain, air, heat, light, nourishment and natural bee pollination—for growing in-season produce all year round. Oishii’s beloved Omakase, Koyo and Nikko Berries are grown in pesticide-free smart farms in the U.S. and proudly bear the Non-GMO Project Verified seal. Founded in 2016, Oishii’s investors include SPARX Asset Management, NTT, Yaskawa, McWin Capital Partners and Resilience Reserve. Oishii was recognized as one of Fast Company’s “World’s Most Innovative Companies” in 2022. For more information, visit www.oishii.com.

SOURCE Oishii

BOSTON, May 12, 2026 — FINTRX, the leading private wealth intelligence platform for asset managers and other investment professionals, today released its inaugural quarterly Family Office Report, with trends and intelligence for the first quarter of 2026. The findings indicate that family offices continue to be led by first-generation entrepreneurs, with a strong and growing preference for direct investments, private equity and venture capital versus hedge funds and fund-of-funds.

In the first quarter of 2026, FINTRX added 119 family offices worldwide to its platform, which now totals 4,503 multi- and single-family offices globally. FINTRX added 75 new single- and 44 multi-family offices to its platform during the quarter, with North America accounting for 49, Europe and Asia/Oceania with 25 each, Africa/Middle East, 13, and Latin America, seven.  

Key findings of the Q1 report include:

• Newly added family offices show a clear preference for actively managed alternatives — including direct investments, private equity, real estate, and venture capital — with select exposure to long-only listed equities and fixed income strategies, and comparatively lower interest in hedge funds and fund-of-funds structures.
• Of the 119 new profiles added during the quarter, single-family offices (SFOs) account for 63%, while multi-family offices (MFOs) make up 52% of the total FINTRX family office database.
• Among the 75 SFOs added during the quarter, 57% are Entrepreneur-origin, driven by wealth created in financial services, real estate, energy, technology and related sectors, and 40% are Generational-origin, driven by real estate, agriculture and financial services.
• FINTRX added 1,904 family office contacts in the quarter, showing a modest uptick in female representation versus the broader database, while leadership roles remain concentrated among men.

“First-generation entrepreneurial families are not just creating more family offices — they are investing in ways that look more like an extension of their business-building experience,” said Patrick Galvin, research associate for FINTRX. “That often means a preference for direct deals, private equity and venture capital, and a more selective approach to commingled fund structures.”

Beyond firm profiles, the report examines the 1,900+ newly added family office contacts, benchmarking them against nearly 30,000 total family office contacts in the FINTRX platform. Managing director, partner and investment analyst rank among the most common titles, reflecting the lean, senior-heavy structures typical of family offices, while prior employment trends point to a strong pipeline from global banks, Big Four accounting firms and leading consulting firms into family office roles.

Methodology
Data in the FINTRX Family Office Report is sourced from the FINTRX private wealth intelligence platform, which tracks more than 4,500 family office profiles and nearly 30,000 contacts across the global wealth channel. Coverage spans single and multi-family offices across all geographies, wealth origins, and investment mandates. All figures reflect the state of the FINTRX database as of March 31, 2026.

To access the full report, visit: https://www.fintrx.com/hubfs/FINTRX%20Q1%202026%20Family%20Office%20Intelligence%20Report.pdf.

About FINTRX
FINTRX is the leading private wealth intelligence platform, offering the industry’s most expansive and up-to-date data on registered investment advisors, broker-dealers, wealth teams, family offices, endowments and foundations. Powered by industry-leading AI, FINTRX helps firms distribute funds, raise capital, recruit advisors, identify M&A targets and drive strategic growth. For more information, visit fintrx.com.

Media contacts
Newton Park PR
Margaret Kirch Cohen
[email protected]
+1 847-507-2229

Kathy Panagopoulos
[email protected]
+1 773-710-7433

SOURCE FINTRX

Snowhawk Capital Digital Opportunities Fund I LP and separate deal-level co-investments support a scaled lower middle market strategy

NEW YORK, May 12, 2026 — Snowhawk LP (“Snowhawk”), a private investment firm focused on digital infrastructure with $1.8 billion of assets under management, today announced the final close of Snowhawk Capital Digital Opportunities Fund I LP (“Fund I”), the firm’s inaugural fund, with approximately $1.3 billion in commitments to Fund I and separate deal-level co-investments.

Fund I will invest in digital infrastructure assets and services across North America, with a focus on control-oriented investments in the lower middle market. The strategy targets businesses that underpin the continued growth of cloud computing and AI, connectivity, and technology-enabled services, where Snowhawk believes its sector specialization and operating capabilities can drive differentiated outcomes.

The close of Fund I marks an important milestone for Snowhawk and reflects strong support from a diverse group of institutional investors, including public and private pension plans, sovereign wealth funds, insurance companies, and other institutions.

Brian McMullen, Managing Partner, said:
“We appreciate the support of our limited partners in establishing Snowhawk’s inaugural fund. We believe the current environment presents a singular, compelling opportunity set in digital infrastructure, particularly in segments of the market where complexity and operational intensity create barriers to entry. Our focus remains on disciplined underwriting and building high-quality platforms alongside management teams.”

Robert D. Reid, Founding Partner, added:
“We have been deliberate in pacing deployment and remain focused on executing transactions with strong fundamentals. Fund I provides the flexibility to pursue broad set of opportunities while maintaining alignment with our investors, and we believe our deep experience positions us as a partner of choice for founder-led businesses.”

Sara Baack, Founding Partner, said:
“Digital infrastructure remains a foundational component of the global economy’s evolution. We are focused on identifying businesses with durable demand drivers and opportunities for strategic and operational value creation, particularly in areas where our experience across cloud, connectivity, and technology services is most relevant.”

Since inception, Snowhawk has deployed capital across a portfolio of investments in digital infrastructure, with four platform investments completed to date and additional opportunities in advanced stages. Snowhawk recently closed its first exit with the sale of portfolio company ProsperOps. Current investments include Prime Data Centers, SecureVision, and CleanArc Data Centers.

About Snowhawk
Snowhawk is a private investment firm that targets strategic majority investments in businesses that power the economy’s digital transition across cloud, connectivity and technology services. Founded in 2022, the Snowhawk team brings long investing histories and deep operating expertise in partnering with management teams to create strong performance and enduring value for companies, customers and investors. For more information, visit snowhawkpartners.com.

SOURCE Snowhawk LP

Funding to accelerate innovation, development, and expansion into new markets and further strengthen its position in defense and commercial autonomy markets 

PROVIDENCE, R.I., May 12, 2026 — Havoc, the all-domain collaborative autonomy company, today announced a $100 million Series A funding round, bringing the company’s total capital raised to ~$200 million since 2024. The round included participation from new investors CCM Capital Markets, Clear Street LLC, Cobalt Capital, Boardman Bay Capital Management, Meet Perry, Mute Ventures, Soren Ventures, SAIC, and JA Green. Existing investors included Outlander VC, Scout VC, B Capital, Lockheed Martin, Taiwania Capital, UP.Partners, and The Veteran Fund, alongside participation from Vanderbilt University’s endowment.

Defense technology is entering a new era where national security priorities are demanding unified, all-domain autonomy. The blueprint for building drones, boats, and vehicles exists. What is missing is the ability for thousands of autonomous assets to work together in a way that is coordinated, collaborative, scalable, and resilient. Havoc’s software-defined hardware approach is unlike anything on the market today, purpose-built to enable autonomous systems across sea, air, and land to operate together as a unified force.

“We built Havoc around a simple belief: the future of national security depends on collaborative autonomy that works in the real world, not in controlled demos or years from now. In less than two years, we’ve already built one of the most mature collaborative autonomy software stacks in the industry, operating across more than 100 air, surface, and ground platforms,” said Paul Lwin, CEO of Havoc. “Our autonomous platforms and command-and-control systems have already demonstrated that they provide warfighters meaningful capability in the exact environments where future conflicts will occur: contested, distributed, and communications-degraded environments. With this funding, we will accelerate deployment across every domain and prove that a single warfighter can task, monitor, and supervise thousands of heterogeneous autonomous systems working together as one force.”

Havoc Fast Facts

• 25,000+ hours of autonomous testing and deployments:
  Validated across sea, air, and land in real-world, contested, and GPS-denied environments. Havoc systems are operational today, with proven ability to build, field, and deliver at speed.
• 200+ billion data points collected from autonomous operations:
  Powers a mature, field-tested autonomy stack across domains, enabling rapid iteration and mission-critical, life-saving outcomes in operational environments.
• 100+ autonomous surface vessels (ASVs) built and deployed:
  Fielded globally across U.S., Europe, and Indo-Pacific, with 40+ mission-ready today and the ability to rapidly scale production to meet demand.
• 30+ vessels delivered to the U.S. Department of Defense:
  Dozens of systems actively supporting DoD missions today, with capacity to scale to thousands of ASVs in 2026 and beyond.
• Strategic acquisitions expanding into air and land domains:
  Acquired Mavrik and Teleo, unifying sea, air, and land systems under a single operational architecture to accelerate all-domain autonomy.
• Strategic partnerships with leading defense primes and integrators:
  Partnerships with Leidos, Lockheed Martin, and SAIC to accelerate deployment of multi-domain autonomy and operational command-and-control systems for the joint force.
• Strategic partnerships with shipbuilders and additive manufacturers (AM):
  Collaborations with PacMar, Senesco, and AM partners enable design, build, and deployment at speed and scale, from rapid prototyping to full-scale production.
• 200+ employees and rapidly scaling:
  Team has more than doubled, expanding engineering, operations, and deployment capacity to meet growing defense and commercial demands.
• Expanded national footprint and production capability:
  New offices in Austin and San Diego, with expanded maritime production in Rhode Island, strengthening access to talent and manufacturing scale.
• Award-winning innovation validated by U.S. Army programs:
  Three-time xTech (Overwatch and Pacific) winner with $6M in SBIR awards, demonstrating operational autonomy across maritime and aerial missions.
• Recognized as a Fast Company Top 10 Most Innovative Company in Defense Tech:
  Named to Fast Company’s Most Innovative Defense Tech Companies of 2026 and selected for the Newlab Global Ocean Innovation Challenge, reflecting validation across defense and commercial markets.
• Board leadership includes former Congressman Devin Nunes:
  As the chair of the President’s Intelligence Advisory Board, Nunes brings deep national security, intelligence, and policy expertise to support Havoc’s growth and government engagement.

The Havoc Difference
Havoc’s software-defined hardware approach enables one-to-many, with a single operator supervising thousands of autonomous assets working together. The Havoc model provides immediate affordable mass by partnering with commercial manufacturers with existing excess capacity.

Havoc delivers real-time decision-making at the edge through all-domain collaborative autonomy, enabling persistent autonomous tasking. Autonomy at the edge fuses sensing, planning, and control, enabling heterogeneous assets to self-organize and execute complex missions with minimal supervision. The Havoc stack is modular and works with any platform or sensor to support autonomous navigation, dynamic path planning, and collision avoidance.

An intuitive, mission focused user interface enables a single operator to command, monitor, and re-task autonomous assets at the scale of thousands, reducing cognitive load and collapsing the distance between operator intent and execution. 

“Havoc has done what very few companies in this space have managed,” said Will Graves, Chief Investment Officer at Boardman Bay Capital Management. “They’ve built a truly scalable collaborative autonomy platform that works across all domains, and the demand signal from the U.S. military speaks for itself. This is exactly the category of hard-tech, defense-critical infrastructure we’re eager to support.”

“Havoc is building foundational infrastructure for how autonomous systems will coordinate and act across every domain,” said Dan Abrams, Managing Partner at Cobalt Capital. “That’s a generational platform opportunity, and exactly the kind of category-defining company Cobalt looks to back. We’re proud to be partners and are incredibly excited about what the future holds for Havoc.”

About Havoc 
Havoc is the leader in all-domain collaborative autonomy. Its software-defined hardware approach powers military and commercial-grade autonomous systems across sea, air, and land to sense, decide, and act together in complex and contested environments. Havoc connects assets, enabling them to share information, adapt in real time, and continue operating even when communications are disrupted or denied. Havoc optimizes mission performance and minimizes human risk. Learn more at havocai.com.

SOURCE Havoc AI

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.

LONDON, May 12, 2026 — Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Billion in Series B funding. This latest round of investment will accelerate the company’s evolution from pioneering novel AI models to applying them at scale.

The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base.

The new capital will be used for the continued development and deployment of Isomorphic Labs’ AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support our existing hiring targets by integrating world-class AI, engineering, drug design, and clinical talent across our sites; this global scale is crucial to Isomorphic Labs’ long-term vision of applying AI-driven breakthroughs to the most complex biological and medical challenges and addressing the global burden of disease.

This funding round serves as further validation of the progress of Isomorphic Labs’ AI drug design capabilities and marks a pivotal moment for the company, demonstrating that its first-principles approach positions it to define the future of AI-driven drug design. By reimagining drug discovery as an integrated scientific and engineering discipline with proprietary AI and data at the core, Isomorphic Labs aims to deliver scientific breakthroughs with a level of precision and speed previously thought impossible.

“The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform,” said Ruth Porat, President and Chief Investment Officer Alphabet and Google. “This trajectory is encouraging, and this funding will be used to accelerate the work and bring important interventions to market with greater speed.”

“This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development,” said Sir Demis Hassabis, Founder and CEO. “Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.”

“This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed,” said Max Jaderberg, President of Isomorphic Labs. “Our drug design engine works, and it’s giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach.”

“We are humbled to have the opportunity to continue to support Isomorphic’s mission to solve all disease,” said Joshua Kushner, Founder and CEO of Thrive Capital. “Over the past year, our conviction in the team has only deepened as they’ve made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design.”

“The caliber of the team Isomorphic has assembled is unmatched, and they continue to validate our belief that this is the premier group at the intersection of AI and drug discovery,” said Dr. Krishna Yeshwant, Managing Partner at GV. “We have strong confidence in Isomorphic. We believe their approach can create important medicines that will be better understood earlier in the process, pushing the boundaries of what’s been possible before.”

Technical Advancement and Strategic Impact

Isomorphic Labs has developed a number of proprietary breakthrough AI models that together form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities. Isomorphic Labs recently published a subset of the powerful and expansive capabilities of IsoDDE, highlighting its predictive accuracy and introducing new capabilities which bridge the gap between structure prediction and real-world drug discovery. IsoDDE offers a scalable foundation for AI drug design, providing the predictive fidelity required to navigate novel biological systems with unprecedented accuracy.

Isomorphic Labs maintains a strong portfolio of strategic partnerships with industry leaders like Novartis, Lilly, and Johnson & Johnson. These collaborations serve as a significant validation of Isomorphic’s AI-first approach and the tangible value it brings to the pharmaceutical industry.

ABOUT ISOMORPHIC LABS

Isomorphic Labs was founded in 2021, to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by CEO Sir Demis Hassabis and President Max Jaderberg. Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has office locations in Cambridge, Massachusetts and Lausanne, Switzerland. Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs. For more information, go to www.isomorphiclabs.com and follow us on LinkedIn and X.

For Media Inquiries
[email protected]

SOURCE Isomorphic Labs